JW (Cayman) Therapeutics Co. Ltd (JWCTF)

Market Cap	122.98M +83.4%
Revenue (ttm)	24.81M +2.8%
Net Income	-86.21M
EPS	-0.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	59,849
Open	0.3070
Previous Close	0.3070
Day's Range	0.3070 - 0.3070
52-Week Range	0.2500 - 0.6602
Beta	2.00
RSI	44.54
Earnings Date	Mar 25, 2026

About JWCTF

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 292
• Stock Exchange: OTCMKTS
• Ticker Symbol: JWCTF

Financial Performance

In 2024, JWCTF's revenue was 158.22 million, a decrease of -8.99% compared to the previous year's 173.86 million. Losses were -590.62 million, -23.10% less than in 2023.

Financial numbers in CNY